News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
745,167 Results
Type
Article (48199)
Company Profile (325)
Press Release (696629)
Multimedia
Podcasts (114)
Webinars (20)
Section
Business (209843)
Career Advice (2210)
Deals (36159)
Drug Delivery (131)
Drug Development (82742)
Employer Resources (196)
FDA (16612)
Job Trends (15354)
News (354002)
Policy (33468)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2763)
Academic (2)
Accelerated approval (34)
Adcomms (27)
Allergies (146)
Alliances (51155)
ALS (174)
Alzheimer's disease (1730)
Antibody-drug conjugate (ADC) (326)
Approvals (16866)
Artificial intelligence (560)
Autoimmune disease (163)
Automation (42)
Bankruptcy (367)
Best Places to Work (11830)
BIOSECURE Act (21)
Biosimilars (194)
Biotechnology (200)
Bladder cancer (161)
Brain cancer (58)
Breast cancer (654)
Cancer (4927)
Cardiovascular disease (414)
Career advice (1874)
Career pathing (40)
CAR-T (297)
CDC (53)
Celiac Disease (2)
Cell therapy (782)
Cervical cancer (37)
Clinical research (70403)
Collaboration (1784)
Company closure (4)
Compensation (1174)
Complete response letters (60)
COVID-19 (2798)
CRISPR (97)
C-suite (900)
Cystic fibrosis (144)
Data (6345)
Decentralized trials (2)
Denatured (40)
Depression (138)
Diabetes (508)
Diagnostics (6869)
Digital health (49)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (272)
Drug pricing (197)
Drug shortages (29)
Duchenne muscular dystrophy (237)
Earnings (91179)
Editorial (62)
Employer branding (25)
Employer resources (167)
Events (121078)
Executive appointments (1014)
FDA (19787)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1535)
Gene editing (208)
Generative AI (49)
Gene therapy (621)
GLP-1 (1018)
Government (4841)
Grass and pollen (6)
Guidances (385)
Healthcare (19268)
HIV (66)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (263)
Immuno-oncology (62)
Indications (118)
Infectious disease (3082)
Inflammatory bowel disease (200)
Inflation Reduction Act (17)
Influenza (120)
Intellectual property (259)
Interviews (350)
IPO (16857)
IRA (53)
Job creations (3857)
Job search strategy (1576)
JPM (61)
Kidney cancer (16)
Labor market (94)
Layoffs (576)
Leadership (35)
Legal (8116)
Liver cancer (92)
Longevity (15)
Lung cancer (669)
Lymphoma (386)
Machine learning (43)
Management (63)
Manufacturing (832)
MASH (168)
Medical device (13939)
Medtech (13996)
Mergers & acquisitions (20381)
Metabolic disorders (1309)
Multiple sclerosis (166)
NASH (22)
Neurodegenerative disease (337)
Neuropsychiatric disorders (91)
Neuroscience (3009)
Neurotech (1)
NextGen: Class of 2026 (6727)
Non-profit (4687)
Now hiring (69)
Obesity (624)
Opinion (288)
Ovarian cancer (169)
Pain (205)
Pancreatic cancer (233)
Parkinson's disease (292)
Partnered (35)
Patents (513)
Patient recruitment (502)
Peanut (59)
People (60999)
Pharmaceutical (73)
Pharmacy benefit managers (29)
Phase 1 (21949)
Phase 2 (30963)
Phase 3 (23074)
Pipeline (5480)
Policy (306)
Postmarket research (2644)
Preclinical (9539)
Press Release (72)
Prostate cancer (242)
Psychedelics (51)
Radiopharmaceuticals (289)
Rare diseases (865)
Real estate (6282)
Recruiting (77)
Regulatory (25034)
Reports (66)
Research institute (2553)
Resumes & cover letters (377)
Rett syndrome (27)
RNA editing (17)
RSV (83)
Schizophrenia (153)
Series A (254)
Series B (197)
Service/supplier (13)
Sickle cell disease (101)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3820)
State (2)
Stomach cancer (19)
Supply chain (108)
Tariffs (84)
The Weekly (72)
Vaccines (1056)
Venture capital (93)
Weight loss (404)
Women's health (95)
Worklife (20)
Date
Today (47)
Last 7 days (574)
Last 30 days (2376)
Last 365 days (30345)
2026 (4070)
2025 (30762)
2024 (35957)
2023 (40864)
2022 (51928)
2021 (56503)
2020 (54901)
2019 (47648)
2018 (35942)
2017 (33098)
2016 (32678)
2015 (38782)
2014 (32378)
2013 (27541)
2012 (29798)
2011 (30537)
2010 (29032)
Location
Africa (815)
Alabama (86)
Alaska (7)
Arizona (320)
Arkansas (14)
Asia (40963)
Australia (6739)
California (11510)
Canada (3346)
China (1124)
Colorado (490)
Connecticut (488)
Delaware (343)
Europe (89398)
Florida (1718)
Georgia (372)
Hawaii (4)
Idaho (62)
Illinois (891)
India (71)
Indiana (539)
Iowa (23)
Japan (443)
Kansas (129)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1411)
Massachusetts (8306)
Michigan (348)
Minnesota (655)
Mississippi (6)
Missouri (130)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (81)
New Jersey (3076)
New Mexico (30)
New York (3050)
North Carolina (1523)
North Dakota (10)
Northern California (5620)
Ohio (342)
Oklahoma (21)
Oregon (41)
Pennsylvania (2319)
Puerto Rico (24)
Rhode Island (48)
South America (1187)
South Carolina (67)
South Dakota (1)
Southern California (4479)
Tennessee (180)
Texas (1793)
United States (41048)
Utah (346)
Vermont (1)
Virginia (269)
Washington D.C. (86)
Washington State (937)
West Virginia (4)
Wisconsin (128)
Wyoming (2)
745,167 Results for "gilead sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
February 11, 2026
·
1 min read
Earnings
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority
With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table.
February 11, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
February 11, 2026
·
19 min read
Press Releases
Gilead Sciences to Present at Upcoming Investor Conference
December 23, 2025
·
1 min read
HIV
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of the HIV market and its plans for business development.
January 14, 2026
·
3 min read
·
Dan Samorodnitsky
Press Releases
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
January 28, 2026
·
1 min read
Earnings
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.
October 31, 2025
·
2 min read
·
Tristan Manalac
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV who are on complex treatment regimens, according to BMO Capital Markets.
November 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
December 19, 2025
·
2 min read
Press Releases
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
January 6, 2026
·
1 min read
1 of 74,517
Next
